Daraxonrasib doubled median overall survival (13.2 vs. 6.6 months) and progression-free survival (7.3 vs. 3.5 months) compared to chemotherapy in previously treated metastatic pancreatic cancer. It also significantly delayed pain deterioration, preserved quality of life longer, and proved much better tolerated, validating a breakthrough RAS(ON) targeting strategy for historically "undruggable" pancreatic tumors.
Research from PathGen showing that Indonesian colorectal cancer (CRC) patients possess a distinct molecular profile with significantly higher rates of oncogenic mutations—specifically 61.88% for RAS and 46.1% for PIK3CA—than Western or regional averages. Notably, 81.25% of probable Lynch syndrome cases and 76.19% of microsatellite instability (MSI) tumors harbored KRAS mutations, challenging traditional assumptions that link Lynch syndrome and MSI primarily to low KRAS mutation rates or BRAF-driven pathways. Because anti-EGFR therapies are ineffective against RAS-mutant cancers, the findings demonstrate that routine RAS testing is essential to prevent unnecessary toxicity and costs in Indonesia, making frontline immunotherapy the preferred strategy while underscoring the need for locally informed precision oncology worldwide.
A study at Dr. Sardjito General Hospital revealed that 21.65% of Indonesian colorectal cancer (CRC) patients are under 50 years old—nearly triple Western rates—alongside a remarkably high 13.85% prevalence of probable Lynch Syndrome. Because young-onset CRC is particularly aggressive and frequently linked to inherited syndromes, the authors urge Indonesia to update national guidelines to mandate universal, affordable PCR-based MSI/MMR testing for patients under 70, preventing ineffective chemotherapy and ensuring access to targeted immunotherapies.